Active	Status	Sponsor type	Region	Phase	Filter
13 Active 11 Inactive 24 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

13 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Hara, Hidehiko
CATALYST, NCT04226547: Amplatzer Amulet LAAO vs. NOAC	Recruiting	N/A	2650	Europe, Canada, Japan, US, RoW	Left Atrial Appendage Occlusion (Amplatzer Amulet LAA Occluder), Amplatzer Amulet LAA Occluder, Non-Vitamin K Oral Antagonists, NOAC	Abbott Medical Devices	Atrial Fibrillation, Stroke, Bleeding	08/27	08/30
Weinreich, Ulla M
NCT06338995: A Study of Lebrikizumab (LY3650150) in Adult Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)	Recruiting	3	510	Europe, Canada, Japan, US, RoW	LY3650150, Placebo, Standard therapy for INCS	Eli Lilly and Company	Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)	11/25	10/26
MATINEE, NCT04133909 / 2018-001540-56: Mepolizumab as Add-on Treatment IN Participants With COPD Characterized by Frequent Exacerbations and Eosinophil Level Jan 2024 - Dec 2024: Acceptance of regulatory submission in US (based on MATINEE trial) for COPD Jan 2024 - Dec 2024: Acceptance of regulatory submission in EU (based on MATINEE trial) for COPD Jan 2024 - Dec 2024: Data from MATINEE trial for COPD Jan 2024 - Dec 2024: Acceptance of regulatory submission in China (based on MATINEE trial) for COPD Jul 2024 - Dec 2024 : Regulatory decision in Japan for COPD	Completed	3	806	Europe, Canada, US, RoW	Placebo, Mepolizumab	GlaxoSmithKline, PPD DEVELOPMENT, LP	Pulmonary Disease, Chronic Obstructive	08/24	08/24
COPDParis, NCT06235502: Long-term Home-based Exercise for Patients With COPD: the COPDtoParis Project	Recruiting	N/A	40	Europe	Home-based cycle-exercise for COPD patients, Standard of Care	Aalborg University Hospital, Karen Elise Jensen Foundation, Simon Fougners Hartmann Family Foundation, 4Mvideo, SENS Innovation Aps	Telerehabilitation, COPD, Quality of Life, Mobility Limitation	09/25	09/25
DUACT, NCT06257667: Treatment of Acute Hypercapnic Respiratory Failure With OptiflowTM or Optiflow+DuetTM Nasal Cannula in COPD-patients	Not yet recruiting	N/A	138	NA	Respiratory Support	Aalborg University Hospital, Bispebjerg Hospital, Viborg Regional Hospital	Hypercapnic Respiratory Failure, COPD	09/25	02/26
Nakamura, Masato
SAVAL, NCT03551496: The DES BTK Vascular Stent System vs PTA in Subjects With Critical Limb Ischemia	Completed	3	201	Europe, Japan, US	Drug Eluting Stent - Below the Knee, Standard PTA Control Arm	Boston Scientific Corporation	Critical Limb Ischemia	04/22	12/23
ALTAIR, NCT04457297: Initial Attack on Latent Metastasis Using TAS-102 for ct DNA Identified Colorectal Cancer Patients After Curative Resection	Recruiting	3	240	Japan, RoW	trifluridine and tipiracil, Placebo	National Cancer Center Hospital East, Alpha-A, Inc.	Colorectal Neoplasms, Trifluridine and Tipiracil, Circulating Tumor DNA	05/23	12/23
NCT04058990: Safety and Effectiveness of Agent Paclitaxel-Coated PTCA Balloon Catheter. (AGENT Japan SV)	Active, not recruiting	N/A	180	Japan	Device: Paclitaxel-Coated PTCA Balloon Catheter, SeQuent Please Drug Eluting Balloon Catheter with Paclitaxel	Boston Scientific Corporation	Coronary Artery Disease	12/21	06/26
NCT03409731: Absorb GT1 Japan PMS	Completed	N/A	135	Japan	ABSORB GT1 BVS	Abbott Medical Devices	Ischemic Heart Disease, Angina Pectoris, Coronary Artery Disease, Coronary Artery Occlusion, Myocardial Ischemia	02/23	02/23
ASET-JAPAN, NCT05117866: Acetyl Salicylic Elimination Trial JAPAN: The ASET JAPAN Pilot Study	Active, not recruiting	N/A	307	Europe, Japan	prasugrel Monotherapy, PCI with the SYNERGY® stent	Meditrix Corp, Fujita Health University, Boston Scientific Japan K.K., National University of Ireland, Galway, Ireland	Chronic Coronary Syndrome, Non ST Segment Elevation Acute Coronary Syndrome	07/24	12/25
Kameda, Hideto
WILLOW, NCT05162586 / 2021-004648-27: The Study With M5049 in SLE and CLE (SCLE and/or DLE) Oct 2024 - Dec 2024 : Data for SLE Jul 2024 - Sep 2024 : Data for CLE	Completed	2	456	Europe, Japan, US, RoW	Enpatoran low dose, M5049, Enpatoran medium dose, Enpatoran high dose, Placebo	EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany	Systemic Lupus Erythematosus	11/24	11/24
Saida, Yoshihisa
JCOG1801, NCT04288999: Surgery Plus Chemo Versus Chemoradiotherapy Followed by Surgery Plus Chemo for Locally Recurrent Rectal Cancer	Recruiting	3	110	Japan	Chemotherapy, CAPOX or mFOLFOX6 or capecitabine or 5-FU+l-LV, Preoperative radiotherapy, Capecitabine plus radiotherapy, Procedure, Surgery	National Cancer Center Hospital East, Japan Clinical Oncology Group, Japan Agency for Medical Research and Development	Rectal Cancer Recurrent	08/25	10/28
Kogame, Norihiro
ASET-JAPAN, NCT05117866: Acetyl Salicylic Elimination Trial JAPAN: The ASET JAPAN Pilot Study	Active, not recruiting	N/A	307	Europe, Japan	prasugrel Monotherapy, PCI with the SYNERGY® stent	Meditrix Corp, Fujita Health University, Boston Scientific Japan K.K., National University of Ireland, Galway, Ireland	Chronic Coronary Syndrome, Non ST Segment Elevation Acute Coronary Syndrome	07/24	12/25
Watanuki, Yoichi
No trials found